Genton E, Barnett H J, Fields W S, Gent M, Hoak J C
Stroke. 1977 Jan-Feb;8(1):150-75. doi: 10.1161/01.str.8.1.150.
A revival of interest in antithrombotic agents for the treatment of ischemic cerebrovascular disease has resulted in the widespread use of oral anticoagulants for the prophylaxis and therapy of the ischemic variety of stroke, and has generated enthusiasm for the use of platelet-suppressant agents such as aspirin, dipyridamole, and sulfinpyrazone. In delineating the several clinical types of focal ischemic disease and outlining the causes of cerebral ischemia and infarction, the study group considers the problems of data interpretation in the face of inconsistent terminology. The basic mechanisms of hemostasis and thrombogenesis are concisely detailed. Finally, the study group critically reviews extensive earlier reports of clinical trials of anticoagulants, platelet function suppressants, and thrombolytic agents, and reassesses according to present-day statistical standards the significance of the results. The information contained in this report should familiarize the reader with sufficient data to permit him to utilize antithrombotic agents under a variety of circumstances and to appreciate the contraindications and potential dangers in their use.
对用于治疗缺血性脑血管疾病的抗血栓形成药物的兴趣再度兴起，导致口服抗凝剂广泛用于缺血性中风的预防和治疗，并引发了对使用血小板抑制剂（如阿司匹林、双嘧达莫和苯磺唑酮）的热情。在描述局灶性缺血性疾病的几种临床类型并概述脑缺血和梗死的原因时，研究小组考虑了面对不一致术语时的数据解释问题。简要详细阐述了止血和血栓形成的基本机制。最后，研究小组批判性地回顾了抗凝剂、血小板功能抑制剂和溶栓剂早期大量的临床试验报告，并根据当今的统计标准重新评估了结果的意义。本报告中包含的信息应使读者熟悉足够的数据，以便他能够在各种情况下使用抗血栓形成药物，并了解其使用中的禁忌症和潜在危险。
